We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Post exposure prophylaxis (PEP) is offered to individuals at high risk of severe chickenpox following an exposure.
JCVI recommends that adults living with adults who are immunosuppressed should be prioritised for the COVID-19 vaccine.
Findings from research by the MHRA have been published, evaluating two different approaches to cancer therapies which harness the immune system to determine which better targets cancer cells and would reduce side effects for patients.
The decision to grant approval for this treatment was endorsed by the government’s independent expert scientific advisory body, the Commission on Human Medicines, after carefully reviewing the evidence.
A new clinical trial will investigate whether a third dose of vaccine for people with weakened immune systems gives a stronger immune response than 2 doses.
Study led by Sheffield and Oxford Universities finds that 99% of people have robust immune response against COVID-19 after one dose of Pfizer vaccine.
UKHSA has been awarded funding to lead a consortium of research partners to better understand how individuals respond to the coronavirus (COVID-19) vaccines.
This group is advised to stay at home at all times, unless for exercise or medical appointments, and not to attend work, even if they are unable to work from home.
Healthcare professionals working in primary and secondary care should ensure that clinically significant immunosuppression in a patient is identified before administration of a live attenuated vaccine.
A review of the benefits and risks of alemtuzumab (including fatal reactions) in the treatment of multiple sclerosis has now concluded and recommended a revised indication, additional contraindications, and strengthened monitoring requirements before, during and after treatment. Patients offered alemtuzumab...
We have recently received 2 reports of fatal adverse reactions to the yellow fever vaccine (Stamaril). Due to an increased risk of life-threatening reactions, the vaccine must not be given to anyone with a medical history of thymus dysfunction or...
Employment Tribunal decision.
Plans to help keep people safe from the cold this winter have been set out by Health Secretary Jeremy Hunt today.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).